Roots Analysis

MARCH 3, 2022

The complement-targeted therapeutics inhibit complement activation, thereby reducing tissue inflammation and dampening the adaptive immune response to foreign and tissue antigens. Broad Clinical Trial Landscape. Next Generation Complement Therapeutics – Current Market Landscape. Next Generation Complement Therapeutics.

Drug Delivery Systems 52

Drug Delivery Systems Marketing Immune Response Dermatology 52

Roots Analysis

FEBRUARY 18, 2022

Over time, many research studies have shown that myeloid cells can interact with the immune system and aid in generating an appropriate anti-tumor immune response. CLINICAL TRIALS EVALUATING MYELOID CELLS TAREGTING THERAPEUTICS. The key focus of these studies is on the development of anti-tumor therapeutics.

Drug Delivery Systems 52

Drug Delivery Systems Immune Response Clinical Trials Clinical Trials 52

Roots Analysis

MAY 21, 2024

The coupling of chemotherapeutic agents with LNPs leads to an increase in the drug levels in tumor tissue and decreases the active therapeutic dose, resistance of drugs and toxicity. The LNPs can be monitored using various imaging modalities to confirm the delivery of siRNA to the target cells.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40